Brief: Diamedica Therapeutics Announces 75% Enrollment Milestone In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
20/05/2026 13:57
May 20 (Reuters) - DiaMedica Therapeutics Inc DMAC.O: DIAMEDICA THERAPEUTICS ANNOUNCES 75% ENROLLMENT MILESTONE IN REMEDY2 PHASE 2/3 ACUTE ISCHEMIC STROKE TRIAL Source text: ID:nBw9gmQNQa Further company coverage: DMAC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program